Clinical Trial Update: Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trastuzumab-pkrb with modified FOLFOX-6 in HER2-positive biliary tract cancer progressed after first-line therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Trastuzumab-pkrb (trastuzumab-pkrb)
• modified FOLFOX-6 (FOLFOX-6)

Snippet

Sponsor: Yonsei University | Conditions: HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer | Phase 2 | Status: COMPLETED